Batonrouge News Reporter

Duchenne Muscular Dystrophy Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Duchenne Muscular Dystrophy Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

July 02
18:06 2021
Duchenne Muscular Dystrophy Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

DelveInsight Business Research LLP
DelveInsight’s “Duchenne Muscular Dystrophy Pipeline Insight” report provides comprehensive insights about keycompanies and pipeline drugs in the Duchenne Muscular Dystrophy pipeline landscapes. It comprises Duchenne Muscular Dystrophy pipeline drug profiles, including clinical and non-clinical stage products.

DelveInsight’s Duchenne Muscular Dystrophy Pipeline Insight report provides comprehensive insights about key companies and pipeline drugs in the Duchenne Muscular Dystrophy pipeline landscapes. It comprises Duchenne Muscular Dystrophy pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Duchenne Muscular Dystrophy therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Duchenne Muscular Dystrophy pipeline products.     

Some of the key takeaways of the Duchenne Muscular Dystrophy Pipeline Report

  • Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Italfarmaco, Catabasis Pharmaceuticals, Santhera Pharmaceuticals, Hoffmann-La Roche, FibroGen, Capricor, Antisense Therapeutics, ReveraGen BioPharma, etc., are developing therapies for the treatment of Duchenne Muscular Dystrophy.

  • Emerging therapies such as Givinostat, Edasalonexent, Idebenone, RG6206 (BMS-986089), Pamrevlumab, CAP-1002, ATL1102, and Vamorolone, are expected to have a significant impact on the  Duchenne Muscular Dystrophy market in the coming years.

Get an overview of pipeline landscape @ Duchenne Muscular Dystrophy Clinical Trials Analysis 

Duchenne muscular dystrophy is a genetic disorder characterized by progressive muscle degeneration and weakness due to the alterations of a protein called dystrophin that helps keep muscle cells intact. DMD is one of four conditions known as dystrophinopathies.

Duchenne Muscular Dystrophy Emerging Drugs

 

  • Givinostat by Italfarmaco 
  • Edasalonexent by Catabasis Pharmaceuticals
  • Idebenone by Santhera Pharmaceuticals
  • RG6206 (BMS-986089) by Hoffmann-La Roche

Scope of Duchenne Muscular Dystrophy Pipeline Drug Insight   

  • Coverage: Global 

  • Major Players: Italfarmaco, Catabasis Pharmaceuticals, Santhera Pharmaceuticals, Hoffmann-La Roche, FibroGen, Capricor, Antisense Therapeutics, ReveraGen BioPharma, and others.

  • Pipeline Therapies: Givinostat, Edasalonexent, Idebenone, RG6206 (BMS-986089), Pamrevlumab, CAP-1002, ATL1102, Vamorolone, and others.

Table of Contents

1

Duchenne Muscular Dystrophy Report Introduction

2

Duchenne Muscular Dystrophy Executive Summary

3

Duchenne Muscular Dystrophy Overview

4

Duchenne Muscular Dystrophy- Analytical Perspective In-depth Commercial Assessment

5

Duchenne Muscular Dystrophy Pipeline Therapeutics

6

Duchenne Muscular Dystrophy Late Stage Products (Phase II/III)

7

Duchenne Muscular Dystrophy Mid Stage Products (Phase II)

8

Duchenne Muscular Dystrophy Early Stage Products (Phase I)

9

Duchenne Muscular Dystrophy Preclinical Stage Products

10

Duchenne Muscular Dystrophy Therapeutics Assessment

11

Duchenne Muscular Dystrophy Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Duchenne Muscular Dystrophy Key Companies

14

Duchenne Muscular Dystrophy Key Products

15

Duchenne Muscular Dystrophy Unmet Needs

16 

Duchenne Muscular Dystrophy Market Drivers and Barriers

17

Duchenne Muscular Dystrophy Future Perspectives and Conclusion

18

Duchenne Muscular Dystrophy Analyst Views

19

Appendix

20

About DelveInsight

Related Reports:

Duchenne Muscular Dystrophy Market 

DelveInsight’s Duchenne Muscular Dystrophy – Market Insights, Epidemiology, and Market Forecast-2030 report deliver an in-depth understanding of the Duchenne Muscular Dystrophy, historical and forecasted epidemiology as well as the Duchenne Muscular Dystrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Duchenne Muscular Dystrophy Epidemiology

DelveInsight’s Duchenne Muscular Dystrophy – Epidemiology Forecast to 2030 report delivers an in-depth understanding of the disease, historical and forecasted Duchenne Muscular Dystrophy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/atlantanewsonlin/public_html/news.batonrougenewsreporter.com/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share

Categories